AC Immune SA Cuts Workforce by 30% to Focus on Key Assets

TL;DR

AC Immune cutting 30% of staff to double down on key drug programs, extending cash runway.

AI Summary

On September 4, 2025, AC Immune SA announced a strategic review resulting in a sharpened focus on its key assets, including three clinical-stage immunotherapy programs and small molecule programs targeting NLRP3 and Tau. This strategic shift will lead to a workforce reduction of approximately 30%, extending the company's cash runway.

Why It Matters

This restructuring indicates a strategic pivot by AC Immune to concentrate resources on its most promising drug candidates, potentially accelerating their development but also signaling a significant operational change.

Risk Assessment

Risk Level: medium — A 30% workforce reduction suggests significant strategic changes and potential challenges in executing its revised plan, while focusing on fewer assets could increase risk if those assets fail.

Key Numbers

• 30% — Workforce Reduction (Indicates a significant restructuring to streamline operations and focus resources.)

Key Players & Entities

• AC Immune SA (company) — Registrant
• September 4, 2025 (date) — Date of press release and announcement
• 30% (percentage) — Workforce reduction percentage
• NLRP3 (drug_target) — Target of small molecule programs
• Tau (drug_target) — Target of small molecule programs

FAQ

Filing Documents

• dp233965_6k.htm (6-K) — 11KB
• dp233965_ex9901.htm (EX-99.1) — 14KB
• image_001.jpg (GRAPHIC) — 2KB
• 0000950103-25-011258.txt ( ) — 29KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On September 4, 2025, AC Immune SA (“ AC Immune ”) issued a press release reporting that, following a strategic review by executive management, AC Immune is sharpening its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, AC Immune will reduce its workforce by around 30% and extend its cash for operations to the end of the third quarter of 2027. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K. This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: September 4, 2025 EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated September 4, 2025

View Full Filing

View this 6-K filing on SEC EDGAR